Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer

SIMPLE SUMMARY: Radioiodine therapy is the main treatment option for metastatic differentiated thyroid cancer (DTC). However, only half of these patients achieve (partial or complete) remission or have stable disease during long-term follow-up. In the remaining ones, disease progresses mainly as the...

Descripción completa

Detalles Bibliográficos
Autores principales: Petranović Ovčariček, Petra, Campenni, Alfredo, de Keizer, Bart, Deandreis, Desiree, Kreissl, Michael C., Vrachimis, Alexis, Tuncel, Murat, Giovanella, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486510/
https://www.ncbi.nlm.nih.gov/pubmed/37686566
http://dx.doi.org/10.3390/cancers15174290
_version_ 1785103023600566272
author Petranović Ovčariček, Petra
Campenni, Alfredo
de Keizer, Bart
Deandreis, Desiree
Kreissl, Michael C.
Vrachimis, Alexis
Tuncel, Murat
Giovanella, Luca
author_facet Petranović Ovčariček, Petra
Campenni, Alfredo
de Keizer, Bart
Deandreis, Desiree
Kreissl, Michael C.
Vrachimis, Alexis
Tuncel, Murat
Giovanella, Luca
author_sort Petranović Ovčariček, Petra
collection PubMed
description SIMPLE SUMMARY: Radioiodine therapy is the main treatment option for metastatic differentiated thyroid cancer (DTC). However, only half of these patients achieve (partial or complete) remission or have stable disease during long-term follow-up. In the remaining ones, disease progresses mainly as they become radioiodine-refractory. The diagnostics of radioiodine-refractory disease are extensively debated. The introduction of novel tracers besides radioiodine isotopes ((131)I, (123)I, and (124)I) and 2-[(18)F]fluoro-2-deoxy-D-glucose ([(18)F]FDG) opens new options for the diagnostics and therapy of this subgroup of DTC patients. Prostate-specific membrane antigen (PSMA) ligands, fibroblast activation protein inhibitors (FAPI), and somatostatin receptor-targeted radiopharmaceuticals appear to be new potential theranostics tracers. In this review, we will elaborate on the role of these radiopharmaceuticals in the management of radioiodine-refractory disease. ABSTRACT: Differentiated thyroid cancer (DTC) is the most common subtype of thyroid cancer and has an excellent overall prognosis. However, metastatic DTC in certain cases may have a poor prognosis as it becomes radioiodine-refractory. Molecular imaging is essential for disease evaluation and further management. The most commonly used tracers are [(18)F]FDG and isotopes of radioiodine. Several other radiopharmaceuticals may be used as well, with different diagnostic performances. This review article aims to summarize radiopharmaceuticals used in patients with radioiodine-refractory DTC (RAI-R DTC), focusing on their different molecular pathways. Additionally, it will demonstrate possible applications of the theranostics approach to this subgroup of metastatic DTC.
format Online
Article
Text
id pubmed-10486510
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104865102023-09-09 Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer Petranović Ovčariček, Petra Campenni, Alfredo de Keizer, Bart Deandreis, Desiree Kreissl, Michael C. Vrachimis, Alexis Tuncel, Murat Giovanella, Luca Cancers (Basel) Review SIMPLE SUMMARY: Radioiodine therapy is the main treatment option for metastatic differentiated thyroid cancer (DTC). However, only half of these patients achieve (partial or complete) remission or have stable disease during long-term follow-up. In the remaining ones, disease progresses mainly as they become radioiodine-refractory. The diagnostics of radioiodine-refractory disease are extensively debated. The introduction of novel tracers besides radioiodine isotopes ((131)I, (123)I, and (124)I) and 2-[(18)F]fluoro-2-deoxy-D-glucose ([(18)F]FDG) opens new options for the diagnostics and therapy of this subgroup of DTC patients. Prostate-specific membrane antigen (PSMA) ligands, fibroblast activation protein inhibitors (FAPI), and somatostatin receptor-targeted radiopharmaceuticals appear to be new potential theranostics tracers. In this review, we will elaborate on the role of these radiopharmaceuticals in the management of radioiodine-refractory disease. ABSTRACT: Differentiated thyroid cancer (DTC) is the most common subtype of thyroid cancer and has an excellent overall prognosis. However, metastatic DTC in certain cases may have a poor prognosis as it becomes radioiodine-refractory. Molecular imaging is essential for disease evaluation and further management. The most commonly used tracers are [(18)F]FDG and isotopes of radioiodine. Several other radiopharmaceuticals may be used as well, with different diagnostic performances. This review article aims to summarize radiopharmaceuticals used in patients with radioiodine-refractory DTC (RAI-R DTC), focusing on their different molecular pathways. Additionally, it will demonstrate possible applications of the theranostics approach to this subgroup of metastatic DTC. MDPI 2023-08-27 /pmc/articles/PMC10486510/ /pubmed/37686566 http://dx.doi.org/10.3390/cancers15174290 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Petranović Ovčariček, Petra
Campenni, Alfredo
de Keizer, Bart
Deandreis, Desiree
Kreissl, Michael C.
Vrachimis, Alexis
Tuncel, Murat
Giovanella, Luca
Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer
title Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer
title_full Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer
title_fullStr Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer
title_full_unstemmed Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer
title_short Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer
title_sort molecular theranostics in radioiodine-refractory differentiated thyroid cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486510/
https://www.ncbi.nlm.nih.gov/pubmed/37686566
http://dx.doi.org/10.3390/cancers15174290
work_keys_str_mv AT petranovicovcaricekpetra moleculartheranosticsinradioiodinerefractorydifferentiatedthyroidcancer
AT campennialfredo moleculartheranosticsinradioiodinerefractorydifferentiatedthyroidcancer
AT dekeizerbart moleculartheranosticsinradioiodinerefractorydifferentiatedthyroidcancer
AT deandreisdesiree moleculartheranosticsinradioiodinerefractorydifferentiatedthyroidcancer
AT kreisslmichaelc moleculartheranosticsinradioiodinerefractorydifferentiatedthyroidcancer
AT vrachimisalexis moleculartheranosticsinradioiodinerefractorydifferentiatedthyroidcancer
AT tuncelmurat moleculartheranosticsinradioiodinerefractorydifferentiatedthyroidcancer
AT giovanellaluca moleculartheranosticsinradioiodinerefractorydifferentiatedthyroidcancer